This week @TMSreach covered #RUA
…being told an “on-going seller” is still on-going BUT keep an eye.
Will Bounce hard when finished. Just how low they go of course first…
Will any news flush seller out first of course? 🧐
https://t.co/BAX09AZP1C
Is the UK ready for the green rush of #medicinalCannabis
“Research shows that when treated with cannabis, one in four will report a 30% or greater improvement in #pain severity”
Right time, right place for @OxCanTech maybe⁉️
#OCTP fully funded remember
https://t.co/U7mSoVQls1
So, with a maintained p/t today announced of 2.6p is #OCTP worth a look?
@TMSreach recently interviewed @OxCanTech CEO @clarissamapson
…have a listen below and see what you think 🎙️
https://t.co/1gAe8D2wRw
We are pleased to share the following update on #OCTP from Edison Group.
Their update notes the following key highlights:
⏺ The initiation and subsequent positive safety data from our Phase I clinical trial for Programme 1 (OCT461201)
Worth a read #OCTP
𝐕𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧: 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐚𝐭 £𝟐𝟓.𝟑𝐦 𝐨𝐫 𝟐.𝟔𝐩
Key highlights included the initiation and subsequent positive safety data from @OxCanTech first Phase I clinical trial and a foray into oncology
Full report ⏬
https://t.co/sYqPM7sOgd
@SmackerAim Thanks Smacker. Like you say I’ve not been away really but just kept myself to myself and kept my opinions and ideas for stocks off Twitter. See what the poll says. I bet Psycho Dave is frantically registering loads of Twitter usernames to vote me to stay away 🤣🤣